Europe Lung Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.
Europe Lung Cancer Diagnostics Market Analysis and Insights
The Europe lung cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. Increasing lung cancer diagnosis and development research is further projected to boost market growth. However, difficulties in lung cancer screening techniques might hamper the growth of the Europe lung cancer diagnostics market in the forecast period.
Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.
The Europe lung cancer diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe lung cancer diagnostics market will grow at a CAGR of 13.3% during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2020 - 2015) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others |
Market Definition
Cancer begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history.
Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
Europe Lung Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
- Increasing early diagnosis of lungs cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
The likelihood of successfully treating cancer is considerably increased by early identification. The two elements of early cancer detection are screening and early diagnosis (or downstaging). While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible.
- Detection of early-stage cancers often limited by high false positives and poor sensitivity
The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.
Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the Europe lung cancer diagnostics market.
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.
- Lack of skilled and certified professionals
The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.
The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.
A cancer diagnosis is a dynamic component in today's complex time, providing patients with essential information for diagnosing, preventing, treating, and managing their cancer disease. The requirement for trained staff is a big issue for the Europe lung cancer diagnostics market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for a cancer diagnosis; this may challenge the growth of the Europe lung cancer diagnostics market.
Post-COVID-19 Impact on Europe Lung Cancer Diagnostics Market
The high burden of COVID-19 on healthcare systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on lung cancer diagnosis and treatment. We investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new lung cancer diagnoses decreased by 34.7% with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in systemic treatment and surgery compared to the pre-COVID-19 era. Compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.
During the pandemic, however, we observed a delay in lung cancer surgery. COVID-19 appears to have significantly impacted lung cancer patients' diagnoses and treatment patterns at our lung cancer center. Many oncologists are concerned that the number of newly diagnosed lung cancer patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to understand better the overall impact of the COVID-19 pandemic on our lung cancer patient population.
Recent Developments
- In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's Europe presence
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases
Europe Lung Cancer Diagnostics Market Scope
The Europe lung cancer diagnostics market is categorized into five notable segments based on product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Europe lung cancer diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
On the basis of test type, the Europe lung cancer diagnostics market is segmented into imaging test, biomarkers test, biopsy, blood test, and others.
Cancer Type
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
On the basis of cancer type, the Europe lung cancer diagnostics market is segmented into non-small cell lung cancer and small cell lung cancer.
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
On the basis of end user, the Europe lung cancer diagnostics market is segmented into hospital, associated labs, independent diagnostics laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the Europe lung cancer diagnostics market is segmented into direct tender and retail sales.
Europe Lung Cancer Diagnostics Market Regional Analysis/Insights
The Europe lung cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.
Some countries covered in the Europe lung cancer diagnostics report Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.
Germany is expected to dominate the Europe lung cancer diagnostics market due to increasing technology and reliability of healthcare services, which also deliver infotainment services.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Lung Cancer Diagnostics Market Share Analysis
The Europe lung cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe lung cancer diagnostics market.
Some players in the Europe lung cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
5 EPIDERMIOLOGY
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER
7.1.3 INCREASING CASES OF LUNG CANCER
7.1.4 RISE IN PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 RISING AWARENESS OF LUNG CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 CT SYSTEMS
8.2.1.2 ULTRASOUND SYSTEMS
8.2.1.3 MRI SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.2.1 NEEDLE BIOPSY
8.2.2.2 ENDOSCOPIC BIOPSY
8.2.2.3 CORE BIOPSY
8.2.2.4 OTHERS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 SLIDE STAINING SYSTEMS
8.2.3.2 TISSUE PROCESSING SYSTEMS
8.2.3.3 CELL PROCESSORS
8.2.3.4 PCR INSTRUMENTS
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES AND ACCESSORIES
8.3.1 KITS
8.3.1.1 DNA POLYMERASE KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 PCR KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.3 CHEST X-RAY
9.2.4 BONE SCAN
9.2.5 MRI
9.2.6 OTHERS
9.3 BIOMARKERS TEST
9.3.1 EGFR MUTATION TEST
9.3.2 KRAS MUTATION TEST
9.3.3 ALK TEST
9.3.4 HER2 TEST
9.3.5 OTHERS
9.4 BIOPSY
9.4.1 NEEDLE BIOPSY
9.4.2 BRONCHOSCOPY BIOPSY
9.4.3 CORE BIOPSY
9.4.4 OTHERS
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT (CBC)
9.5.2 BLOOD CHEMISTRY TESTS
9.5.3 OTHERS
9.6 OTHERS
10 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 NON-SMALL CELL LUNG CANCER
10.3 SMALL CELL LUNG CANCER
11 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 ASSOCIATED LABS
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES
11.5 DIAGNOSTIC IMAGING CENTERS
11.6 CANCER RESEARCH INSTITUTES
11.7 OTHERS
12 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 FRANCE
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 RUSSIA
13.1.7 NETHERLANDS
13.1.8 SWITZERLAND
13.1.9 TURKEY
13.1.10 BELGIUM
13.1.11 POLAND
13.1.12 DENMARK
13.1.13 SWEDEN
13.1.14 NORWAY
13.1.15 FINLAND
13.1.16 REST OF EUROPE
14 EUROPE LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 F. HOFFMANN-LA ROCHE LTD. (2022)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC. (2022)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ABBOTT (2022)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 QUEST DIAGNOSTICS INCORPORATED (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 BIODESIX (2022)
16.5.1 COMPANY PROFILE
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 AMOY DIAGNOSTICS CO., LTD. (2022)
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BIO-RAD LABORATORIES, INC. (2022)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIOCARTIS (2022)
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BODITECH MED INC.
16.9.1 COMPANY PROFILE
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 DANAHER (2022)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 DIASORIN S.P.A. (2022)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022)
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 20/20 GENE SYSTEMS
16.13.1 COMPANY PROFILE
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 GUARDANT HEALTH INC.
16.14.1 COMPANY PROFILE
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 INIVATA LTD.
16.15.1 COMPANY PROFILE
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 LALPATHLABS.COM (2022)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 LUNGLIFE AI, INC. (2022)
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MEDGENOME
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MYRIAD GENETICS, INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 NEOGENOMICS LABORATORIES (2022)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
16.21 NANOSTRING (2022)
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENTS
16.22 NANOENTEK
16.22.1 COMPANY PROFILE
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 ONCOCYTE CORPORATION
16.23.1 COMPANY PROFILE
16.23.2 SERVICE PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 PERKINELMER INC
16.24.1 COMPANY PROFILE
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENTS
16.25 PLEXBIO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
16.26 QIAGEN
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENTS
16.27 SIEMENS HEALTHCARE GMBH
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENTS
16.28 VERACYTE, INC. (2022)
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENTS
16.29 VELA DIAGNOSTICS
16.29.1 COMPANY PROFILE
16.29.2 PRODUCT PORTFOLIO
16.29.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LUNG CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER
TABLE 4 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 EUROPE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 EUROPE NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 EUROPE HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 34 EUROPE DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 EUROPE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 EUROPE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 EUROPE IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 EUROPE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 EUROPE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 44 EUROPE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 53 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 GERMANY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 GERMANY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 GERMANY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 GERMANY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 GERMANY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 GERMANY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 GERMANY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 GERMANY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 GERMANY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 GERMANY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 GERMANY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.K. INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 U.K. PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.K. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.K. BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 U.K. CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.K. KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.K. REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 U.K. BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.K. IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.K. BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 U.K. BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 84 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 85 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 FRANCE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 FRANCE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 FRANCE. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 FRANCE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 FRANCE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 FRANCE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 FRANCE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 FRANCE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 FRANCE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 FRANCE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 FRANCE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 100 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 101 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 ITALY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 ITALY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 ITALY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 ITALY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 ITALY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 ITALY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 ITALY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 ITALY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 ITALY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 ITALY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 ITALY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 115 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 117 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 SPAIN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 SPAIN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 SPAIN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 SPAIN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 SPAIN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 SPAIN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 SPAIN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 SPAIN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 SPAIN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 SPAIN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 SPAIN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 133 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 134 RUSSIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 RUSSIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 RUSSIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 RUSSIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 RUSSIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 RUSSIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 RUSSIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 RUSSIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 RUSSIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 RUSSIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 147 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 NETHERLANDS INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 NETHERLANDS IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 NETHERLANDS BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 154 NETHERLANDS CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 NETHERLANDS KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 NETHERLANDS REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 NETHERLANDS BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 NETHERLANDS IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 NETHERLANDS BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 NETHERLANDS BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 163 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 SWITZERLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 168 SWITZERLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 169 SWITZERLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 170 SWITZERLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 SWITZERLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 SWITZERLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 SWITZERLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 SWITZERLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 SWITZERLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 SWITZERLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 179 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 TURKEY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 TURKEY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 184 TURKEY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 185 TURKEY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 TURKEY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 TURKEY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 TURKEY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 TURKEY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 191 TURKEY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 TURKEY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 TURKEY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 194 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 195 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 196 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 197 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 198 BELGIUM INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 200 BELGIUM IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 201 BELGIUM BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 202 BELGIUM CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 203 BELGIUM KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 BELGIUM REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 BELGIUM BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 BELGIUM IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 208 BELGIUM BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 209 BELGIUM BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 211 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 212 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 213 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 214 POLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 215 POLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 POLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 POLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 POLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 POLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 POLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 POLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 223 POLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 POLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 POLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 227 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 228 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 229 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 230 DENMARK INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 DENMARK PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 DENMARK IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 DENMARK BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 DENMARK CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 235 DENMARK KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 236 DENMARK REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 238 DENMARK BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 239 DENMARK IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 240 DENMARK BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 241 DENMARK BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 242 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 243 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 245 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 246 SWEDEN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 247 SWEDEN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 248 SWEDEN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 249 SWEDEN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 250 SWEDEN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 251 SWEDEN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 252 SWEDEN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 254 SWEDEN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 255 SWEDEN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 256 SWEDEN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 257 SWEDEN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 258 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 259 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 260 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 261 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 262 NORWAY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 263 NORWAY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 264 NORWAY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 265 NORWAY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 266 NORWAY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 267 NORWAY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 268 NORWAY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 269 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 270 NORWAY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 271 NORWAY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 272 NORWAY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 273 NORWAY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 274 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 275 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 276 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 277 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 278 FINLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 279 FINLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 280 FINLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 281 FINLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 282 FINLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 283 FINLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 284 FINLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 285 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 286 FINLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 287 FINLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 288 FINLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 289 FINLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 290 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 291 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LUNG CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE EUROPE LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LUNG CANCER DIAGNOSTICS MARKET
FIGURE 14 THE EUROPE MORTALITY RATE DUE TO CANCER
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING EUROPE CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 18 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 19 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 20 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 22 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 23 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 24 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 25 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 30 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 31 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 32 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 34 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 35 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 36 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 42 EUROPE LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
